Skip to content

FDA Clears Fasikl’s AI-Powered Felix NeuroAI Wristband for Essential Tremor

 | 

Fasikl, a neurotechnology company spun out of the University of Minnesota, has received FDA 510(k) clearance for its Felix™ NeuroAI™ Wristband, a noninvasive, AI-driven wearable designed to reduce upper limb tremors in adults with essential tremor (ET)—a condition affecting approximately 7 million people in the U.S.

Essential tremor is the most common movement disorder in the U.S., causing involuntary, rhythmic shaking—most often in the hands—that can make simple daily tasks like drinking from a glass, writing, or buttoning a shirt extremely difficult. Treatment options for essential tremor have traditionally been limited. Medications often provide inconsistent relief and are accompanied by undesirable side effects. More invasive solutions like deep brain stimulation and focused ultrasound can be effective but require surgical intervention, which may not be feasible or desirable for many patients, particularly older adults or those with comorbidities.

The Felix NeuroAI wristband reportedly represents a noninvasive alternative that offers a new level of personalization. Worn on the wrist, the device connects to Fasikl’s cloud-based AI platform, which enables continuous adaptation of stimulation based on neural signals captured from peripheral nerves. This allows the Felix device to deliver personalized therapy in real time, reportedly providing all-day symptom relief while integrating easily into a user’s daily life.

The FDA clearance was supported by strong clinical evidence from the TRANQUIL study, a randomized, double-blind, sham-controlled trial involving 125 adults across 12 clinical sites in the U.S. and China. Participants were assigned in a 2:1 ratio to receive either the Felix wristband or a sham device for 90 days. The study met its primary endpoint, demonstrating statistically and clinically significant reductions in tremors and improvements in daily activity performance. No serious device-related adverse events were reported. These results were presented at the American Academy of Neurology (AAN) annual meeting in April 2025.

Fasikl CEO Dr. Zhi Yang said the clearance “marks a defining moment for Fasikl and the millions of people living with essential tremor who have long been underserved by existing therapies.” He further noted that “this breakthrough in non-invasive, intelligent, and personalized neuromodulation marks the emergence of AI therapeutics in disease treatment,” offering “a new option that is potentially more effective, safer, and more scalable.”

The Felix NeuroAI Wristband will be available by prescription in select U.S. regions beginning in 2025, with national availability expected in 2026.

Tags

, , , ,

FDA Clears Fasikl’s AI-Powered Felix NeuroAI Wristband for Essential Tremor Headshot

Raina Patel

Fasikl, a neurotechnology company spun out of the University of Minnesota, has received FDA 510(k) clearance for its Felix™ NeuroAI™ Wristband, a noninvasive, AI-driven wearable designed to reduce upper limb...

View all posts published by Raina Patel
By using this blog, you agree and understand that no information is being provided in the context of any attorney-client relationship. You further agree and understand that nothing herein is intended to be legal advice. This blog is solely informational in nature, and is not intended as, and should not be used as, a substitute for competent legal advice from a retained and licensed attorney in your state. Knobbe Martens LLP makes no representations or warranties as to the accuracy, completeness, timeliness or availability of the information in this blog. Knobbe Martens LLP will not be liable for any injury or damages relating to your use of, or access to, any such information. Knobbe Martens LLP undertakes no obligation to correct or update information on this blog, which may be incorrect or become incorrect or out of date over time. Knobbe Martens LLP reserves the right to alter or delete content or information on the blog at any time. This blog contains links and references to other websites and publications that you may find of interest. Knobbe Martens LLP does not control, promote, endorse or otherwise have any affiliation with any other websites or publications unless those websites or publications expressly state such an affiliation. Knobbe Martens LLP further has no responsibility for, and makes no representations regarding, the content, accuracy or any other aspect of the information in such websites or publications.
close modal